Skip to main content
Top
Published in: European Radiology 12/2023

Open Access 20-07-2023 | Primary Sclerosing Cholangitis | Hepatobiliary-Pancreas

Diagnosis of functional strictures in patients with primary sclerosing cholangitis using hepatobiliary contrast-enhanced MRI: a proof-of-concept study

Authors: Sarah Poetter-Lang, Alina Messner, Nina Bastati, Kristina I. Ringe, Maxime Ronot, Sudhakar K. Venkatesh, Raphael Ambros, Antonia Kristic, Aida Korajac, Gregor Dovjak, Martin Zalaudek, Jacqueline. C. Hodge, Christoph Schramm, Emina Halilbasic, Michael Trauner, Ahmed Ba-Ssalamah

Published in: European Radiology | Issue 12/2023

Login to get access

Abstract

Objectives

PSC strictures are routinely diagnosed on T2-MRCP as dominant- (DS) or high-grade stricture (HGS). However, high inter-observer variability limits their utility. We introduce the “potential functional stricture” (PFS) on T1-weighted hepatobiliary-phase images of gadoxetic acid-enhanced MR cholangiography (T1-MRC) to assess inter-reader agreement on diagnosis, location, and prognostic value of PFS on T1-MRC vs. DS or HGS on T2-MRCP in PSC patients, using ERCP as the gold standard.

Methods

Six blinded readers independently reviewed 129 MRIs to diagnose and locate stricture, if present. DS/HGS was determined on T2-MRCP. On T1-MRC, PFS was diagnosed if no GA excretion was seen in the CBD, hilum or distal RHD, or LHD. If excretion was normal, “no functional stricture” (NFS) was diagnosed. T1-MRC diagnoses (NFS = 87; PFS = 42) were correlated with ERCP, clinical scores, labs, splenic volume, and clinical events. Statistical analyses included Kaplan–Meier curves and Cox regression.

Results

Interobserver agreement was almost perfect for NFS vs. PFS diagnosis, but fair to moderate for DS and HGS. Forty-four ERCPs in 129 patients (34.1%) were performed, 39 in PFS (92.9%), and, due to clinical suspicion, five in NFS (5.7%) patients. PFS and NFS diagnoses had 100% PPV and 100% NPV, respectively. Labs and clinical scores were significantly worse for PFS vs. NFS. PFS patients underwent more diagnostic and therapeutic ERCPs, experienced more clinical events, and reached significantly more endpoints (p < 0.001) than those with NFS. Multivariate analysis identified PFS as an independent risk factor for liver-related events.

Conclusion

T1-MRC was superior to T2-MRCP for stricture diagnosis, stricture location, and prognostication.

Clinical relevance statement

Because half of PSC patients will develop clinically-relevant strictures over the course of the disease, earlier more confident diagnosis and correct localization of functional stricture on gadoxetic acid-enhanced MRI may optimize management and improve prognostication.

Key Points

There is no consensus regarding biliary stricture imaging features in PSC that have clinical relevance.
Twenty-minute T1-weighted MRC images correctly classified PSC patients with potential (PFS) vs with no functional stricture (NFS).
T1-MRC diagnoses may reduce the burden of diagnostic ERCPs.

Graphical abstract

Appendix
Available only for authorised users
Literature
1.
go back to reference Singh S, Talwalkar JA (2013) Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol 11:898–907PubMedPubMedCentral Singh S, Talwalkar JA (2013) Primary sclerosing cholangitis: diagnosis, prognosis, and management. Clin Gastroenterol Hepatol 11:898–907PubMedPubMedCentral
2.
go back to reference Fung BM, Lindor KD, Tabibian JH (2019) Cancer risk in primary sclerosing cholangitis: epidemiology, prevention, and surveillance strategies. World J Gastroenterol 25:659–671PubMedPubMedCentral Fung BM, Lindor KD, Tabibian JH (2019) Cancer risk in primary sclerosing cholangitis: epidemiology, prevention, and surveillance strategies. World J Gastroenterol 25:659–671PubMedPubMedCentral
3.
go back to reference Bjornsson E, Lindqvist-Ottosson J, Asztely M, Olsson R (2004) Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 99:502–508PubMed Bjornsson E, Lindqvist-Ottosson J, Asztely M, Olsson R (2004) Dominant strictures in patients with primary sclerosing cholangitis. Am J Gastroenterol 99:502–508PubMed
4.
go back to reference Hilscher MB, Tabibian JH, Carey EJ, Gostout CJ, Lindor KD (2018) Dominant strictures in primary sclerosing cholangitis: a multicenter survey of clinical definitions and practices. Hepatol Commun 2:836–844PubMedPubMedCentral Hilscher MB, Tabibian JH, Carey EJ, Gostout CJ, Lindor KD (2018) Dominant strictures in primary sclerosing cholangitis: a multicenter survey of clinical definitions and practices. Hepatol Commun 2:836–844PubMedPubMedCentral
5.
go back to reference Aabakken L, Karlsen TH, Albert J et al (2017) Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Endoscopy 49:588–608PubMed Aabakken L, Karlsen TH, Albert J et al (2017) Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) Clinical Guideline. Endoscopy 49:588–608PubMed
6.
go back to reference European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L (2022) EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol 77:761–806 European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L (2022) EASL Clinical Practice Guidelines on sclerosing cholangitis. J Hepatol 77:761–806
7.
go back to reference Zenouzi R, Liwinski T, Yamamura J et al (2018) Follow-up magnetic resonance imaging/3D-magnetic resonance cholangiopancreatography in patients with primary sclerosing cholangitis: challenging for experts to interpret. Aliment Pharmacol Ther 48:169–178PubMed Zenouzi R, Liwinski T, Yamamura J et al (2018) Follow-up magnetic resonance imaging/3D-magnetic resonance cholangiopancreatography in patients with primary sclerosing cholangitis: challenging for experts to interpret. Aliment Pharmacol Ther 48:169–178PubMed
9.
go back to reference Ruiz A, Lemoinne S, Carrat F, Corpechot C, Chazouilleres O, Arrive L (2014) Radiologic course of primary sclerosing cholangitis: assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression. Hepatology 59:242–250PubMed Ruiz A, Lemoinne S, Carrat F, Corpechot C, Chazouilleres O, Arrive L (2014) Radiologic course of primary sclerosing cholangitis: assessment by three-dimensional magnetic resonance cholangiography and predictive features of progression. Hepatology 59:242–250PubMed
10.
go back to reference Ponsioen CY, Assis DN, Boberg KM et al (2021) Defining primary sclerosing cholangitis: results from an International Primary Sclerosing Cholangitis Study Group Consensus Process. Gastroenterology 161(1764–1775):e1765 Ponsioen CY, Assis DN, Boberg KM et al (2021) Defining primary sclerosing cholangitis: results from an International Primary Sclerosing Cholangitis Study Group Consensus Process. Gastroenterology 161(1764–1775):e1765
11.
go back to reference Ba-Ssalamah A, Qayyum A, Bastati N, Fakhrai N, Herold CJ, Caseiro Alves F (2014) P4 radiology of hepatobiliary diseases with gadoxetic acid-enhanced MRI as a biomarker. Expert Rev Gastroenterol Hepatol 8:147–160PubMed Ba-Ssalamah A, Qayyum A, Bastati N, Fakhrai N, Herold CJ, Caseiro Alves F (2014) P4 radiology of hepatobiliary diseases with gadoxetic acid-enhanced MRI as a biomarker. Expert Rev Gastroenterol Hepatol 8:147–160PubMed
12.
go back to reference Neri E, Bali MA, Ba-Ssalamah A et al (2016) ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol 26:921–931PubMed Neri E, Bali MA, Ba-Ssalamah A et al (2016) ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol 26:921–931PubMed
13.
go back to reference Reiner CS, Merkle EM, Bashir MR, Walle NL, Nazeer HK, Gupta RT (2013) MRI assessment of biliary ductal obstruction: is there added value of T1-weighted gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MR cholangiography? AJR Am J Roentgenol 201:W49-56PubMed Reiner CS, Merkle EM, Bashir MR, Walle NL, Nazeer HK, Gupta RT (2013) MRI assessment of biliary ductal obstruction: is there added value of T1-weighted gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced MR cholangiography? AJR Am J Roentgenol 201:W49-56PubMed
14.
go back to reference Ringe KI, Husarik DB, Gupta RT, Boll DT, Merkle EM (2011) Hepatobiliary transit times of gadoxetate disodium (Primovist(R)) for protocol optimization of comprehensive MR imaging of the biliary system–what is normal? Eur J Radiol 79:201–205PubMed Ringe KI, Husarik DB, Gupta RT, Boll DT, Merkle EM (2011) Hepatobiliary transit times of gadoxetate disodium (Primovist(R)) for protocol optimization of comprehensive MR imaging of the biliary system–what is normal? Eur J Radiol 79:201–205PubMed
15.
go back to reference Nolz R, Asenbaum U, Schoder M et al (2014) Diagnostic workup of primary sclerosing cholangitis: the benefit of adding gadoxetic acid-enhanced T1-weighted magnetic resonance cholangiography to conventional T2-weighted magnetic resonance cholangiography. Clin Radiol 69:499–508PubMed Nolz R, Asenbaum U, Schoder M et al (2014) Diagnostic workup of primary sclerosing cholangitis: the benefit of adding gadoxetic acid-enhanced T1-weighted magnetic resonance cholangiography to conventional T2-weighted magnetic resonance cholangiography. Clin Radiol 69:499–508PubMed
16.
go back to reference Frydrychowicz A, Jedynak AR, Kelcz F, Nagle SK, Reeder SB (2012) Gadoxetic acid-enhanced T1-weighted MR cholangiography in primary sclerosing cholangitis. J Magn Reson Imaging 36:632–640PubMedPubMedCentral Frydrychowicz A, Jedynak AR, Kelcz F, Nagle SK, Reeder SB (2012) Gadoxetic acid-enhanced T1-weighted MR cholangiography in primary sclerosing cholangitis. J Magn Reson Imaging 36:632–640PubMedPubMedCentral
17.
go back to reference Giambelluca D, Cutaia G, Midiri M, Salvaggio G (2019) The “pruned tree” appearance of primary sclerosing cholangitis. Abdom Radiol (NY) 44:2935–2936PubMed Giambelluca D, Cutaia G, Midiri M, Salvaggio G (2019) The “pruned tree” appearance of primary sclerosing cholangitis. Abdom Radiol (NY) 44:2935–2936PubMed
19.
go back to reference Bastati N, Beer L, Mandorfer M et al (2020) Does the functional liver imaging score derived from gadoxetic acid-enhanced MRI predict outcomes in chronic liver disease? Radiology 294:98–107PubMed Bastati N, Beer L, Mandorfer M et al (2020) Does the functional liver imaging score derived from gadoxetic acid-enhanced MRI predict outcomes in chronic liver disease? Radiology 294:98–107PubMed
20.
go back to reference Bastati N, Wibmer A, Tamandl D et al (2016) Assessment of orthotopic liver transplant graft survival on gadoxetic acid-enhanced magnetic resonance imaging using qualitative and quantitative parameters. Invest Radiol 51:728–734PubMed Bastati N, Wibmer A, Tamandl D et al (2016) Assessment of orthotopic liver transplant graft survival on gadoxetic acid-enhanced magnetic resonance imaging using qualitative and quantitative parameters. Invest Radiol 51:728–734PubMed
21.
go back to reference Ruemmele P, Hofstaedter F, Gelbmann CM (2009) Secondary sclerosing cholangitis. Nat Rev Gastroenterol Hepatol 6:287–295PubMed Ruemmele P, Hofstaedter F, Gelbmann CM (2009) Secondary sclerosing cholangitis. Nat Rev Gastroenterol Hepatol 6:287–295PubMed
22.
go back to reference de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VIIF (2022) Baveno VII - Renewing consensus in portal hypertension. J Hepatol 76:959–974PubMed de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C, Baveno VIIF (2022) Baveno VII - Renewing consensus in portal hypertension. J Hepatol 76:959–974PubMed
23.
go back to reference Goet JC, Floreani A, Verhelst X et al (2019) Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis. J Hepatol 71:992–999PubMed Goet JC, Floreani A, Verhelst X et al (2019) Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis. J Hepatol 71:992–999PubMed
24.
go back to reference Acar S, Akyildiz M (2019) A new prognostic model for primary sclerosing cholangitis. Turk J Gastroenterol 30:1004–1006PubMedPubMedCentral Acar S, Akyildiz M (2019) A new prognostic model for primary sclerosing cholangitis. Turk J Gastroenterol 30:1004–1006PubMedPubMedCentral
25.
go back to reference Goode EC, Clark AB, Mells GF et al (2019) Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system. Hepatology 69:2120–2135PubMed Goode EC, Clark AB, Mells GF et al (2019) Factors associated with outcomes of patients with primary sclerosing cholangitis and development and validation of a risk scoring system. Hepatology 69:2120–2135PubMed
26.
go back to reference Lemoinne S, Cazzagon N, El Mouhadi S et al (2019) Simple magnetic resonance scores associate with outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 17(2785–2792):e2783 Lemoinne S, Cazzagon N, El Mouhadi S et al (2019) Simple magnetic resonance scores associate with outcomes of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 17(2785–2792):e2783
27.
go back to reference Hoeffel C, Azizi L, Lewin M et al (2006) Normal and pathologic features of the postoperative biliary tract at 3D MR cholangiopancreatography and MR imaging. Radiographics 26:1603–1620PubMed Hoeffel C, Azizi L, Lewin M et al (2006) Normal and pathologic features of the postoperative biliary tract at 3D MR cholangiopancreatography and MR imaging. Radiographics 26:1603–1620PubMed
28.
go back to reference Schramm C, Eaton J, Ringe KI, Venkatesh S, Yamamura J, IPSCSG MRIwgot (2017) Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group. Hepatology 66:1675–1688PubMed Schramm C, Eaton J, Ringe KI, Venkatesh S, Yamamura J, IPSCSG MRIwgot (2017) Recommendations on the use of magnetic resonance imaging in PSC-A position statement from the International PSC Study Group. Hepatology 66:1675–1688PubMed
29.
go back to reference Aljiffry M, Renfrew PD, Walsh MJ, Laryea M, Molinari M (2011) Analytical review of diagnosis and treatment strategies for dominant bile duct strictures in patients with primary sclerosing cholangitis. HPB (Oxford) 13:79–90PubMed Aljiffry M, Renfrew PD, Walsh MJ, Laryea M, Molinari M (2011) Analytical review of diagnosis and treatment strategies for dominant bile duct strictures in patients with primary sclerosing cholangitis. HPB (Oxford) 13:79–90PubMed
30.
go back to reference Tenca A, Mustonen H, Lind K et al (2018) The role of magnetic resonance imaging and endoscopic retrograde cholangiography in the evaluation of disease activity and severity in primary sclerosing cholangitis. Liver Int 38:2329–2339PubMed Tenca A, Mustonen H, Lind K et al (2018) The role of magnetic resonance imaging and endoscopic retrograde cholangiography in the evaluation of disease activity and severity in primary sclerosing cholangitis. Liver Int 38:2329–2339PubMed
31.
go back to reference Khoshpouri P, Ameli S, Ghasabeh MA et al (2018) Correlation between quantitative liver and spleen volumes and disease severity in primary sclerosing cholangitis as determined by Mayo risk score. Eur J Radiol 108:254–260PubMed Khoshpouri P, Ameli S, Ghasabeh MA et al (2018) Correlation between quantitative liver and spleen volumes and disease severity in primary sclerosing cholangitis as determined by Mayo risk score. Eur J Radiol 108:254–260PubMed
32.
go back to reference Fernandez-Placencia R, Golse N, Cano L et al (2020) Spleen volumetry and liver transient elastography: predictors of persistent posthepatectomy decompensation in patients with hepatocellular carcinoma. Surgery 168:17–24PubMed Fernandez-Placencia R, Golse N, Cano L et al (2020) Spleen volumetry and liver transient elastography: predictors of persistent posthepatectomy decompensation in patients with hepatocellular carcinoma. Surgery 168:17–24PubMed
33.
go back to reference Tafur M, Cheung A, Menezes RJ et al (2020) Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled transient elastography. Eur Radiol 30:3735–3747PubMed Tafur M, Cheung A, Menezes RJ et al (2020) Risk stratification in primary sclerosing cholangitis: comparison of biliary stricture severity on MRCP versus liver stiffness by MR elastography and vibration-controlled transient elastography. Eur Radiol 30:3735–3747PubMed
34.
go back to reference Prassopoulos P, Daskalogiannaki M, Raissaki M, Hatjidakis A, Gourtsoyiannis N (1997) Determination of normal splenic volume on computed tomography in relation to age, gender and body habitus. Eur Radiol 7:246–248PubMed Prassopoulos P, Daskalogiannaki M, Raissaki M, Hatjidakis A, Gourtsoyiannis N (1997) Determination of normal splenic volume on computed tomography in relation to age, gender and body habitus. Eur Radiol 7:246–248PubMed
35.
go back to reference Jung F, Cazzagon N, Vettorazzi E et al (2019) Rate of spleen length progression is a marker of outcome in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 17:2613–2615PubMed Jung F, Cazzagon N, Vettorazzi E et al (2019) Rate of spleen length progression is a marker of outcome in patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 17:2613–2615PubMed
36.
go back to reference Lindor KD, Kowdley KV, Harrison ME, American College of G (2015) ACG Clinical Guideline: primary sclerosing cholangitis. Am J Gastroenterol 110:646–659 (quiz 660)PubMed Lindor KD, Kowdley KV, Harrison ME, American College of G (2015) ACG Clinical Guideline: primary sclerosing cholangitis. Am J Gastroenterol 110:646–659 (quiz 660)PubMed
37.
go back to reference Baluyut AR, Sherman S, Lehman GA, Hoen H, Chalasani N (2001) Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 53:308–312PubMed Baluyut AR, Sherman S, Lehman GA, Hoen H, Chalasani N (2001) Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. Gastrointest Endosc 53:308–312PubMed
38.
go back to reference Rupp C, Hippchen T, Bruckner T et al (2019) Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis. Gut 68:2170–2178PubMed Rupp C, Hippchen T, Bruckner T et al (2019) Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis. Gut 68:2170–2178PubMed
39.
go back to reference Erlinger S (1985) What is cholestasis in 1985? J Hepatol 1:687–693PubMed Erlinger S (1985) What is cholestasis in 1985? J Hepatol 1:687–693PubMed
41.
go back to reference Nilsson H, Blomqvist L, Douglas L et al (2014) Dynamic gadoxetate-enhanced MRI for the assessment of total and segmental liver function and volume in primary sclerosing cholangitis. J Magn Reson Imaging 39:879–886PubMed Nilsson H, Blomqvist L, Douglas L et al (2014) Dynamic gadoxetate-enhanced MRI for the assessment of total and segmental liver function and volume in primary sclerosing cholangitis. J Magn Reson Imaging 39:879–886PubMed
42.
go back to reference Ringe KI, Hinrichs J, Merkle EM, Weismuller TJ, Wacker F, Meyer BC (2014) Gadoxetate disodium in patients with primary sclerosing cholangitis: an analysis of hepatobiliary contrast excretion. J Magn Reson Imaging 40:106–112PubMed Ringe KI, Hinrichs J, Merkle EM, Weismuller TJ, Wacker F, Meyer BC (2014) Gadoxetate disodium in patients with primary sclerosing cholangitis: an analysis of hepatobiliary contrast excretion. J Magn Reson Imaging 40:106–112PubMed
43.
go back to reference Ehlken H, Wroblewski R, Corpechot C et al (2016) Validation of transient elastography and comparison with spleen length measurement for staging of fibrosis and clinical prognosis in Primary Sclerosing Cholangitis. PLoS One 11:e0164224PubMedPubMedCentral Ehlken H, Wroblewski R, Corpechot C et al (2016) Validation of transient elastography and comparison with spleen length measurement for staging of fibrosis and clinical prognosis in Primary Sclerosing Cholangitis. PLoS One 11:e0164224PubMedPubMedCentral
44.
go back to reference Villard C, Friis-Liby I, Rorsman F et al (2023) Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis. J Hepatol 78:604–613PubMed Villard C, Friis-Liby I, Rorsman F et al (2023) Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis. J Hepatol 78:604–613PubMed
45.
go back to reference Boonstra K, Weersma RK, van Erpecum KJ et al (2013) Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 58:2045–2055PubMed Boonstra K, Weersma RK, van Erpecum KJ et al (2013) Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 58:2045–2055PubMed
Metadata
Title
Diagnosis of functional strictures in patients with primary sclerosing cholangitis using hepatobiliary contrast-enhanced MRI: a proof-of-concept study
Authors
Sarah Poetter-Lang
Alina Messner
Nina Bastati
Kristina I. Ringe
Maxime Ronot
Sudhakar K. Venkatesh
Raphael Ambros
Antonia Kristic
Aida Korajac
Gregor Dovjak
Martin Zalaudek
Jacqueline. C. Hodge
Christoph Schramm
Emina Halilbasic
Michael Trauner
Ahmed Ba-Ssalamah
Publication date
20-07-2023
Publisher
Springer Berlin Heidelberg
Published in
European Radiology / Issue 12/2023
Print ISSN: 0938-7994
Electronic ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-023-09915-3

Other articles of this Issue 12/2023

European Radiology 12/2023 Go to the issue